Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker

In order to search for early changes induced by the application of human immunoglobulin G (IgG) on motor nerve terminals, IgG from patients with amyotrophic lateral sclerosis (ALS) and control subjects was injected subcutaneously into the levator auris muscle of mice. A week or a month after the las...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado: 2000
Materias:
Acceso en línea:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0148639X_v23_n4_p543_Fratantoni
http://hdl.handle.net/20.500.12110/paper_0148639X_v23_n4_p543_Fratantoni
Aporte de:
id paper:paper_0148639X_v23_n4_p543_Fratantoni
record_format dspace
spelling paper:paper_0148639X_v23_n4_p543_Fratantoni2023-06-08T15:13:11Z Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker Amyotrophic lateral sclerosis Calcium channels Neuromuscular junction Nitrendipine Transmitter release calcium channel blocking agent immunoglobulin G nitrendipine adult aged amyotrophic lateral sclerosis animal cell animal model animal tissue article calcium transport clinical article controlled study female human human cell human tissue immunotherapy male mouse nerve cell necrosis neurotransmitter release nonhuman priority journal protein expression voltage clamp Adult Aged Animals Calcium Channel Blockers Calcium Channels, L-Type Evoked Potentials Female Humans Immunoglobulin G Male Mice Middle Aged Motor Neuron Disease Muscle, Skeletal Neuromuscular Junction Nitrendipine omega-Agatoxin IVA omega-Conotoxin GVIA Reference Values In order to search for early changes induced by the application of human immunoglobulin G (IgG) on motor nerve terminals, IgG from patients with amyotrophic lateral sclerosis (ALS) and control subjects was injected subcutaneously into the levator auris muscle of mice. A week or a month after the last injection, endplate potentials were recorded. No changes in quantal content of transmitter release were observed. In control and ALS IgG-treated muscles, neurotransmitter release remained sensitive to P/Q-type and insensitive to N-type voltage-sensitive calcium channel (VSCC) blockers as in untreated muscles. In contrast, IgG from 5 of 8 different ALS patients induced a significant reduction in quantal content of the evoked response after incubation with nitrendipine, indicating that a novel sensitivity to this calcium channel blocker appears in these motor nerve terminals. These results indicate that ALS IgG induces plastic changes at nerve terminals. The expression of transmitter release coupled to L-type VSCC indicate that ALS IgGs are capable of inducing plastic changes at the nerve terminals that may participate in the process leading to neuronal death. (C) 2000 John Wiley and Sons, Inc. 2000 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0148639X_v23_n4_p543_Fratantoni http://hdl.handle.net/20.500.12110/paper_0148639X_v23_n4_p543_Fratantoni
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic Amyotrophic lateral sclerosis
Calcium channels
Neuromuscular junction
Nitrendipine
Transmitter release
calcium channel blocking agent
immunoglobulin G
nitrendipine
adult
aged
amyotrophic lateral sclerosis
animal cell
animal model
animal tissue
article
calcium transport
clinical article
controlled study
female
human
human cell
human tissue
immunotherapy
male
mouse
nerve cell necrosis
neurotransmitter release
nonhuman
priority journal
protein expression
voltage clamp
Adult
Aged
Animals
Calcium Channel Blockers
Calcium Channels, L-Type
Evoked Potentials
Female
Humans
Immunoglobulin G
Male
Mice
Middle Aged
Motor Neuron Disease
Muscle, Skeletal
Neuromuscular Junction
Nitrendipine
omega-Agatoxin IVA
omega-Conotoxin GVIA
Reference Values
spellingShingle Amyotrophic lateral sclerosis
Calcium channels
Neuromuscular junction
Nitrendipine
Transmitter release
calcium channel blocking agent
immunoglobulin G
nitrendipine
adult
aged
amyotrophic lateral sclerosis
animal cell
animal model
animal tissue
article
calcium transport
clinical article
controlled study
female
human
human cell
human tissue
immunotherapy
male
mouse
nerve cell necrosis
neurotransmitter release
nonhuman
priority journal
protein expression
voltage clamp
Adult
Aged
Animals
Calcium Channel Blockers
Calcium Channels, L-Type
Evoked Potentials
Female
Humans
Immunoglobulin G
Male
Mice
Middle Aged
Motor Neuron Disease
Muscle, Skeletal
Neuromuscular Junction
Nitrendipine
omega-Agatoxin IVA
omega-Conotoxin GVIA
Reference Values
Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker
topic_facet Amyotrophic lateral sclerosis
Calcium channels
Neuromuscular junction
Nitrendipine
Transmitter release
calcium channel blocking agent
immunoglobulin G
nitrendipine
adult
aged
amyotrophic lateral sclerosis
animal cell
animal model
animal tissue
article
calcium transport
clinical article
controlled study
female
human
human cell
human tissue
immunotherapy
male
mouse
nerve cell necrosis
neurotransmitter release
nonhuman
priority journal
protein expression
voltage clamp
Adult
Aged
Animals
Calcium Channel Blockers
Calcium Channels, L-Type
Evoked Potentials
Female
Humans
Immunoglobulin G
Male
Mice
Middle Aged
Motor Neuron Disease
Muscle, Skeletal
Neuromuscular Junction
Nitrendipine
omega-Agatoxin IVA
omega-Conotoxin GVIA
Reference Values
description In order to search for early changes induced by the application of human immunoglobulin G (IgG) on motor nerve terminals, IgG from patients with amyotrophic lateral sclerosis (ALS) and control subjects was injected subcutaneously into the levator auris muscle of mice. A week or a month after the last injection, endplate potentials were recorded. No changes in quantal content of transmitter release were observed. In control and ALS IgG-treated muscles, neurotransmitter release remained sensitive to P/Q-type and insensitive to N-type voltage-sensitive calcium channel (VSCC) blockers as in untreated muscles. In contrast, IgG from 5 of 8 different ALS patients induced a significant reduction in quantal content of the evoked response after incubation with nitrendipine, indicating that a novel sensitivity to this calcium channel blocker appears in these motor nerve terminals. These results indicate that ALS IgG induces plastic changes at nerve terminals. The expression of transmitter release coupled to L-type VSCC indicate that ALS IgGs are capable of inducing plastic changes at the nerve terminals that may participate in the process leading to neuronal death. (C) 2000 John Wiley and Sons, Inc.
title Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker
title_short Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker
title_full Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker
title_fullStr Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker
title_full_unstemmed Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker
title_sort amyotrophic lateral sclerosis igg-treated neuromuscular junctions develop sensitivity to l-type calcium channel blocker
publishDate 2000
url https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0148639X_v23_n4_p543_Fratantoni
http://hdl.handle.net/20.500.12110/paper_0148639X_v23_n4_p543_Fratantoni
_version_ 1768541603748642816